We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
- Authors
Danilov, A.; Gregory, G. P.; Morschhauser, F.; Cheah, C. Y.; Shah, H.; Jurczak, W.; Olabode, D.; Meyer, S.; Yoon, J. L.; Arduini, S.; Saeh, J.; Olsson, R. F.; Strati, P.
- Abstract
B Introduction: b AZD4573, a potent and highly selective CDK9i, rapidly induces apoptosis in human haematologic cancer cell lines. PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) In a first-in-human trial, AZD4573 monotherapy had manageable safety in pts with I r/r i haematologic cancers and antitumour activity in those with DLBCL.
- Subjects
DIFFUSE large B-cell lymphomas
- Publication
Hematological Oncology, 2023, Vol 41, p129
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_87